Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease

Narayan, Vivek; Thompson, Elizabeth; Demissei, Biniyam G.; Ho, Jennifer E.; Januzzi, James L.; Ky, Bonnie

doi:10.1016/j.jacc.2020.03.067

Cited by 66 publications

(47 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Published data have demonstrated the long-term stability of endogenous NT-proBNP, sST2, and galectin-3 for 4 months, 18 months, and 3 months, respectively, but little is known about stability over longer periods of time [ 37 , 38 , 39 ]. It is also important to note that there is overlap between the pathophysiology of CVD and cancer, including inflammation and cellular proliferation [ 40 ], which may affect the utility of these biomarkers for cardiovascular disease detection amongst cancer survivors in clinical practice. In addition, the fact that galectin-3 levels can be elevated due to liver cirrhosis and pulmonary fibrosis and that sST2 can be elevated due to diabetes and hypertension may have impacted the results as well [ 15 , 41 ].…”

Section: Discussionmentioning

confidence: 99%

N-Terminal Pro Brain Natriuretic Peptide, sST2, and Galectin-3 Levels in Breast Cancer Survivors

Patel

Herrmann

Vierkant

et al. 2021

JCM

View full text Add to dashboard Cite

NT-proBNP, soluble ST2 (sST2), and galectin-3 are biomarkers of cardiac dysfunction that have been proposed as identifiers of patients experiencing asymptomatic cardiac dysfunction after anthracycline-based chemotherapy. This study aimed to compare the proportion of breast cancer (BC) survivors with elevated serum levels of these three putative biomarkers by prior receipt of anthracycline (yes vs. no). Five-hundred-eighty survivors of BC who had received anthracycline-based chemotherapy were matched by age and time between diagnosis and serum storage to 580 who had not. Cardiac biomarker levels were analyzed using immunoassays. Analyses were carried out using linear and logistic regression models. Anthracycline recipients had higher values of NT-proBNP than non-recipients (mean 116.0 ng/L vs. 97.0 ng/L, respectively; p < 0.001). Values for ST2 and galectin-3 did not significantly differ by receipt of anthracycline. After further adjustment for age at breast cancer diagnosis, ethnicity, and receipt of trastuzumab, associations between receipt of anthracycline and higher NT-proBNP persisted (p < 0.001), showing that NT-proBNP may be a biomarker of cardiovascular toxicity after receipt of anthracycline-based chemotherapy. Further research to assess the clinical utility of NT-proBNP testing after receipt of anthracycline is recommended. sST2 and galectin-3 do not appear to differentiate between anthracycline recipients and non-recipients amongst breast cancer survivors.

show abstract

Section: Discussionmentioning

confidence: 99%

N-Terminal Pro Brain Natriuretic Peptide, sST2, and Galectin-3 Levels in Breast Cancer Survivors

Patel

Herrmann

Vierkant

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Cardiovascular diseases and cancer share several common pathophysiological mechanisms for the incidence and progression of the disease. In the recently published review by Narayan et al (22), Several markers common to both diseases were highlighted, in an attempt to understand the relationship between cardiovascular disease and cancer through fundamental biological processes common to CVD and cancer, including inflammation, cell proliferation, resistance to death neurohormonal stress, angiogenesis, and genomic instability. Papers of Interleukin 6, highly sensitive C-reactive protein (hsCRP), interleukin-33, suppression of tumorigenicity, galectin-3, growth differentiation factor 15 (GDF-15), cardiac troponin T, neurohormones such as NT-proBNP were reviewed.…”

Section: Mechanistic Biomarkers Of Cardiovascular Disease and Cancermentioning

confidence: 99%

Cardiopulmonary bypass and cancer dissemination and progression: myth reality, enigma, puzzle?

Li¹,

Wada²,

Évora³

2023

Curr Chall Thorac Surg

View full text Add to dashboard Cite

Cardiac disease (CD) and oncologic disease (OD) are among the most lethal diseases. Both share common risk factors and as a consequence, there are a substantial number of patients who need surgeries for problems related to both diseases. Treatments for OD should start as soon as possible, as the disease can progress and disseminate, reducing life expectancy for patients. At times, heart problems may need cardiac surgery (CS), which are sophisticated and peculiar, at many times needing a machine to do the lung and the heart function as the surgeon does his job. This is called cardiopulmonary bypass (CPB), a procedure that is known to be related to inflammation and immunosuppression syndromes, that could lead the cancer disease to disseminate. There is little information on this subject in the literature so, in this narrative review, we have made a literature review, trying to address whether this theoretical worry confirms at evidencebased medicine. We also described some considerations regarding the use of devices like Cell Saver ® and autotransfusion in oncologic patients. Further, we have taken some considerations about what care should be taken when facing situations with patients of different stages of OD needing CS and what should be discussed multidisciplinary aiming a treatment that best fits patient's life-expectancy and clinical status.

show abstract

“…По данным международных рекомендаций к клиническим симптомам кардиотоксичности относятся: боли в сердце, учащенное или затрудненное дыхание, цианоз (диффузный), отек лодыжек и голеностопных суставов, асцит, гепатомегалия, артериальная гипотония или АГ, хрипы в легких, кашель, пароксизмальная ночная одышка, выбухание яремных вен и плевральный выпот [35,36]. Для диагностики и мониторинга кардиотоксичности АЦ рекомендуется ЭКГ в 12 отведениях с расчетом QTc (QTc=QT/√RR), ЭхоКГ, оценка уровня тропонина I и натрийуретического пептида В-типа [37,38]. Применение АЦ связано с наджелудочковой аритмией и желудочковой экстрасистолией во время или сразу после введения препарата [14].…”

Section: таблицаunclassified

“…В настоящее время в качестве биомаркеров кардиотоксичности на фоне терапии противоопухолевыми препаратами рассматриваются высокочувствительный С-реактивный белок, галектин-3, белок ST 2 (стимулирующий фактор роста, экспрессируемый геном 2), нейротензин, GDF15 (growth differentiation factor 15), PlGF (placental growth factor) и т.д. [38], поскольку они являются маркерами ишемического повреждения миокарда, сосудистого воспаления, повреждения тканей, а также индикаторами прогрессирования СН, причем как у лиц с ЗНО, так и ССЗ [38].…”

Section: таблицаunclassified

Cardiovascular complications in patients with cancer: focus on anthracycline-induced cardiotoxicity

Муркамилов

Айтбаев

Фомин

et al. 2021

Cardiovasc Ther Prev

View full text Add to dashboard Cite

The article describes prevalence and risk factors of cardiovascular in patients with cancer. The problems of anthracycline-induced cardiotoxicity, the deleterious effects of doxorubicin on the heart, as well as the cardioprotective effects of beta-blockers and agents acting on the renin-angiotensin-aldosterone system pathway are discussed. By cardiotoxicity is implied the development of various adverse cardiovascular events against the background of drug therapy for cancer patients. Depending on the severity of myocardial damage, there are type I (anthracycline-mediated cardiotoxicity, myocardial damage is irreversible) and type II (trastuzumab-mediated cardiotoxicity, myocardial dysfunction is reversible) cardiotoxicity. Anthracycline-induced cardiotoxicity, in turn, is divided into acute, early-onset chronic and late-onset chronic. At the same time, the main mechanisms of anthracycline cytotoxicity in relation to healthy cardiomyocytes are stimulation of intracellular oxidative stress, a decrease in reduced glutathione concentration, inhibition of cell redox potential, and a change in iron metabolism. The article discusses in detail the risk factors (age, hypertension, diabetes, asymptomatic left ventricular dysfunction, documented cardiovascular diseases, heart failure, etc.), as well as the mechanisms and treatment of anthracycline-mediated cardiotoxicity.

show abstract

Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease

Cited by 66 publications

References 106 publications

N-Terminal Pro Brain Natriuretic Peptide, sST2, and Galectin-3 Levels in Breast Cancer Survivors

N-Terminal Pro Brain Natriuretic Peptide, sST2, and Galectin-3 Levels in Breast Cancer Survivors

Cardiopulmonary bypass and cancer dissemination and progression: myth reality, enigma, puzzle?

Cardiovascular complications in patients with cancer: focus on anthracycline-induced cardiotoxicity

Contact Info

Product

Resources

About